Daxor Corporation DAXOR Corporation is a publicly traded company registered on NYSE MKT (DXR). We are an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.
Our IDANT division provides (1) semen banking services, which include anonymous donor semen and semen storage, (2) autologous blood storage, (3) andrology services, which include semen analysis and sperm washing, and (4) general lab testing.
Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee, which conducts its equipment manufacturing, testing and development of models of the BVA-100.
Ultimately the company’s mission is to help hospitals and physicians incorporate DAXOR’s advanced technologies to significantly improve the quality of patient care.
NYSE MKT : DXR
3,990,906 shares outstanding
3,447,779 as of March 17th total amount of shares held by insiders and institutional investors
Daxor Receives Notification of Patent Approval and Issues an Update on its Stock Buyback Program
NEW YORK, NY--(Marketwired - Mar 17, 2015) - Daxor Corporation (NYSE MKT: DXR), a medical instrumentation and biotechnology company, announced the approval of a patent and an update on its stock buyback program.
Daxor has received notification from the U.S. Patent Office that its patents for the total body albumin analyzer and its supplementary patent on its Blood Volume Analyzer filed on October 25, 2011, have been approved.
The actual patent is expected to be issued within the next 30 to 60 days. The patents for the total body albumin analyzer are the first patents ever issued for an instrument to measure the total albumin within the human body. Albumin is the major carri
er molecule in the human body for hundreds of metabolic products such as hormones. Albumin is also the major protein responsible for maintaining blood pressure within the body. Many diseases such as congestive heart failure, diabetes, kidney disease, involve loss of albumin concentration within a person's circulation. When this occurs, a drop in blood pressure occurs resulting in a shift of fluid from the circulation into the fluid space between individual body cells. Patients with low albumin frequently develop peripheral edema. The most dangerous derangement is pulmonary edema which leads to water in the lungs and is particularly problematic when someone has heart failure. Albumin is a vastly underutilized therapeutic agent derived from human blood. The ability to precisely quantify the total amount of albumin in an individual patient should provide opportunities for its therapeutic use in the conditions where its absence leads to major blood volume derangements. The total body albumin measurement is performed in conjunction with a blood volume measurement.
The company will begin production of the BVA-200 which will enable hospitals to obtain both total body blood volume and total body albumin measurements. Hospitals with the existing BVA-100 will be able to obtain upgrades which will enable them to perform this test. The major producer of albumin in the U.S. is Baxter International Inc.
At the American College of Cardiology conference held in San Diego from March 13th through March 17th, Dr. Wayne Miller of the Mayo Clinic presented research data on congestive heart failure patients utilizing the blood volume analyzer for advanced diagnostic evaluation.
On March 16th, the Company repurchased 44,145 shares of its common stock. The total amount of shares held by insiders and institutional investors as of March 17th is 3,447,779. Of this amount, 3,168,846 shares are held by insiders and 278,933 shares are held by institutional investors. The company has in place a program which allows it to repurchase up to 250,000 shares each year. Since January 1st, the company has repurchased 84,627 shares of its common stock.
As of December 31, 2014, the Company had net assets of $24,580,735 or $6.16 per share.
To learn more about Daxor, please visit www.Daxor.com.
What is the BVA-100?
The BVA-100 (Blood Volume Analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body.
Blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. Due to these issues, blood volume measurements were very rarely done. Physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations.
The BVA-100 can measure blood volume: accurately, quickly & reliably.
In under 60 minutes, the BVA-100 can accurately measure blood volume. In an emergency, doctors can get initial results within 30 minutes. In addition to accurately measuring a patient’s blood volume, the BVA-100 can also determine each individual patient’s normal blood volume and compares the measured volume to what is normal for that patient.
For the first time, physicians can have access to incredible technology that enables them to receive precise blood volume measurements very quickly in clinical situations where traditional measures such as hemacrotit and hemoglobin are not reliable. Peer reviewed studies have shown to be the most reliable and accurate measure of a patient’s true blood volume available in a clinical setting.
Results The BVA-100 will help with more accurate diagnoses, more insight to patients, better health, and lower costs over the lifetime of the patient.
Blood volume measurements can be very involved in diagnosing and determining what the best treatment option would be for a number of acute and chronic medical conditions.
Red Cell Mass
The red cell mass is a test that is usually requested by hematologists so they can measure the amount of red blood cells that are in a patient. This is a crucial test that they run to determine the health status of a patient that is going through chemotherapy. The original method of performing this test was using a complicated and time-consuming test based on a using a specific type of chromium isotope called Cr51. Physicians have been put at a disadvantage because this specific chromium has been taken off the market, hence prohibiting them from performing this type of test to help their patients.
Fortunately the BVA-100 machine enables physicians to once again be able to perform this type of test on their patients.
How the BVA-100 Compares to the Discontinued Chromium Test:
Results are obtained in under 1 hour compared to the 8 hours or more with the Chromium test
Results are more accurate
More information is available – the test also gives data on the total blood volume and plasma volume that is in the patients body
Proven in Clinical studies to be a much better quality test than the discontinued Chromium test
There are many medical conditions and medications which can alter your blood volume that the BVA-100 can help a physician diagnose. Being able to diagnose any blood volume irregularities that may not be visible from a physical exam or other lab tests, will help to identify the best possible treatment for these following conditions:
1.) Congestive Heart Failure
4.) Syncope/Orthostatic Hypotension
6.) Chronic Fatigue
7.) Pre/Post Surgical Testing
8.) Septic Shock
9.)Red Cell Mass Test
How the BVA-100 Works
Basic Principle of Blood Volume Measurement
Blood volume analysis is based on the fundamental concept of the indicator dilution technique, whereby a tracer substance, in this case albumin I-131, is mixed into an unknown volume. An identical amount of tracer is placed into a known volume. By comparing the concentration of the indicator between the known and unknown volumes, an exact measurement of the unknown volume can be obtained.
How Does the BVA Provide Accurate Blood Volume Measurement?
The BVA-100 is a semi-automated blood volume analyzer. The instrument is used in conjunction with a single-use injection kit consisting of a precisely measured standard and matching injectate. The injectate is packaged in a patented flow chamber designed to ensure 99.8%+ delivery. The kit improves accuracy and eliminates the many time-consuming and difficult steps required for on-site standard preparation.
The BVA-100 utilizes five separate sampling points taken at regular intervals starting approximately 12 minutes after injection. In effect, each sample measurement is a separate, single-point blood volume determination. The BVA-100 computes the transudation time for the tracer and calculates the true zero point blood volume with an accuracy of approximately ± 2.5%. The BVA-100 provides interim blood volume results while the samples are being measured; preliminary data is available within 30 minutes and may be used to guide decisions in emergency situations.
Summary of the Basic Technical Steps to Perform a Blood Volume Analysis
1.) Enter patient data (patient’s name, hospital number, accurate height and weight measurement
2.) Inject tracer through IV line, record injection time for the beginning of the blood volume measurement
3.) Collect blood sample into anti-coagulated tube via specialized collection kit requiring a single venipuncture
4.) Obtain microhematocrit and centrifuge samples to separate plasma
5.) Pipette 1 cc plasma samples and place into Blood Volume Analyzer
Repeat steps 3, 4, and 5 for samples 2 through 5; preliminary results will be available within 30 minutes after injection. Blood volume analysis is complete, with final results available after 90 minutes.
Technical Requirements of Personnel
Ability to establish an intravenous line and collect blood samples
Basic technical expertise in performing hematocrits and familiarity with accurate pipetting technique.